Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 243

1.

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.

Kim JJ, Goldie SJ.

BMJ. 2009 Oct 8;339:b3884. doi: 10.1136/bmj.b3884.

PMID:
19815582
[PubMed - indexed for MEDLINE]
Free PMC Article
2.
3.

Health and economic implications of HPV vaccination in the United States.

Kim JJ, Goldie SJ.

N Engl J Med. 2008 Aug 21;359(8):821-32. doi: 10.1056/NEJMsa0707052.

PMID:
18716299
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.

Kim JJ, Ortendahl J, Goldie SJ.

Ann Intern Med. 2009 Oct 20;151(8):538-45.

PMID:
19841455
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

Annemans L, Rémy V, Oyee J, Largeron N.

Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006.

PMID:
19354343
[PubMed - indexed for MEDLINE]
6.

Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.

Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S.

Curr Med Res Opin. 2008 May;24(5):1473-83. doi: 10.1185/030079908X297826 . Epub 2008 Apr 14.

PMID:
18413014
[PubMed - indexed for MEDLINE]
7.

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G.

Sex Health. 2007 Sep;4(3):165-75.

PMID:
17931529
[PubMed - indexed for MEDLINE]
8.

Economic evaluation of human papillomavirus vaccination in the United Kingdom.

Jit M, Choi YH, Edmunds WJ.

BMJ. 2008 Jul 17;337:a769. doi: 10.1136/bmj.a769.

PMID:
18640957
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.

Demarteau N, Van Kriekinge G, Simon P.

Vaccine. 2013 Aug 20;31(37):3962-71. doi: 10.1016/j.vaccine.2013.06.008. Epub 2013 Jun 15.

PMID:
23777952
[PubMed - indexed for MEDLINE]
Free Article
10.

The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting.

Kim JJ, Andres-Beck B, Goldie SJ.

Br J Cancer. 2007 Nov 5;97(9):1322-8. Epub 2007 Oct 9.

PMID:
17923869
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

de Kok IM, van Ballegooijen M, Habbema JD.

J Natl Cancer Inst. 2009 Aug 5;101(15):1083-92. doi: 10.1093/jnci/djp183. Epub 2009 Jul 1.

PMID:
19571256
[PubMed - indexed for MEDLINE]
Free Article
12.

A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females.

Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau N.

BMC Public Health. 2009 Oct 31;9:401. doi: 10.1186/1471-2458-9-401.

PMID:
19878578
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.

Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH.

J Med Econ. 2010 Mar;13(1):110-8. doi: 10.3111/13696990903546013.

PMID:
20085477
[PubMed - indexed for MEDLINE]
14.

Cost-effectiveness of different human papillomavirus vaccines in Singapore.

Lee VJ, Tay SK, Teoh YL, Tok MY.

BMC Public Health. 2011 Mar 31;11:203. doi: 10.1186/1471-2458-11-203.

PMID:
21453537
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

The cost-effectiveness of male HPV vaccination in the United States.

Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE.

Vaccine. 2011 Oct 26;29(46):8443-50. doi: 10.1016/j.vaccine.2011.07.096. Epub 2011 Aug 2.

PMID:
21816193
[PubMed - indexed for MEDLINE]
16.

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.

Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ.

BJOG. 2012 Jan;119(2):166-76. doi: 10.1111/j.1471-0528.2011.02974.x. Epub 2011 Apr 12.

PMID:
21481160
[PubMed - indexed for MEDLINE]
17.

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.

Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V.

Int J Technol Assess Health Care. 2008 Winter;24(1):10-9. doi: 10.1017/S0266462307080026.

PMID:
18218164
[PubMed - indexed for MEDLINE]
18.

Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.

Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC.

Vaccine. 2013 Aug 20;31(37):3863-71. doi: 10.1016/j.vaccine.2013.06.064. Epub 2013 Jul 3.

PMID:
23830974
[PubMed - indexed for MEDLINE]
19.

Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.

Yamamoto N, Mori R, Jacklin P, Osuga Y, Kawana K, Shibuya K, Taketani Y.

BJOG. 2012 Jan;119(2):177-86. doi: 10.1111/j.1471-0528.2011.03036.x. Epub 2011 Jul 28.

PMID:
21794070
[PubMed - indexed for MEDLINE]
20.

Age-based programs for vaccination against HPV.

Elbasha EH, Dasbach EJ, Insinga RP, Haupt RM, Barr E.

Value Health. 2009 Jul-Aug;12(5):697-707. doi: 10.1111/j.1524-4733.2009.00512.x.

PMID:
19490561
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk